| Patents for A61K 35 - Medicinal preparations containing material or reaction products thereof with undetermined constitution (125,838) |
|---|
| 09/27/2001 | WO2001070130A2 Compositions derived from modiolus modiolus and methods for making and using same |
| 09/27/2001 | WO2001030754A3 Micro-cluster liquids and methods of making and using them |
| 09/27/2001 | WO2001019824A3 New active marine alkaloids |
| 09/27/2001 | WO2001016296A3 Use of cytokines, cells, and mitogens to inhibit graft versus host disease |
| 09/27/2001 | WO2001012831A3 Anti-bacterial and anti-viral compositions and methods |
| 09/27/2001 | WO2000057837A8 Compositions and methods for effecting the levels of cholesterol |
| 09/27/2001 | WO2000041707A3 USE OF $i(LACTOBACILLUS SALIVARIUS) |
| 09/27/2001 | US20010025058 Therapy for fungus infections |
| 09/27/2001 | US20010025026 Chimeric proteins for use in transport of a selected substance into cells |
| 09/27/2001 | US20010024827 Which express a neuron-specific marker and which can give rise to progeny which can differentiate into neuronal cells; for treatment of neuronal disorders |
| 09/27/2001 | US20010024824 Stem cells and their use in transplantation |
| 09/27/2001 | US20010024822 Culturing human cells with the use of a culture device having an affinity for protein |
| 09/27/2001 | US20010024817 Viral nucleotide sequences |
| 09/27/2001 | US20010024781 Substituted-2,3,4,10-tetrahydrobenzo(g)pteridin-2,4-diones; decontamination of blood, protein and blood products as well as other fluids such as juices, and surfaces of food, carcasses, bathing surfaces |
| 09/27/2001 | US20010024650 Artery - and vein-specific proteins and uses therefor |
| 09/27/2001 | CA2406993A1 Multifunctional polypeptides comprising a binding site to an epitope of the nkg2d receptor complex |
| 09/27/2001 | CA2403818A1 Matrices containing nitric oxide donors and reducing agents and their use |
| 09/27/2001 | CA2403795A1 Osteocalcin promoter directed adenovirus replicaton for therapy |
| 09/27/2001 | CA2403684A1 Therapeutic anti-melanoma compounds |
| 09/27/2001 | CA2403671A1 Compositions derived from modiolus modiolus and methods for making and using same |
| 09/27/2001 | CA2403572A1 Fibroblast growth factor receptor-like molecules and uses thereof |
| 09/27/2001 | CA2403491A1 Use of lactic acid bacterium for the prevention of peritonitis |
| 09/27/2001 | CA2403359A1 Cross-reactive displacing antibodies from collagen-binding proteins and method of identification and use |
| 09/27/2001 | CA2402816A1 Antisense nucleic acid molecules targeted to type i collagenase (mmp-1) for inhibition of melanoma invasion |
| 09/27/2001 | CA2402722A1 Sperm factor oscillogenin |
| 09/26/2001 | EP1136571A2 Detection of polymorphisms in the MxA gene to predict the response of an hepatitis C virus infected individual to interferon therapy |
| 09/26/2001 | EP1136561A2 Targeting gene therapy |
| 09/26/2001 | EP1136084A1 Compositions containing thrombin and process for their manufacture |
| 09/26/2001 | EP1135688A2 Methods and compositions useful for targeting activated vitronectin receptor alpha(nu)-beta(3) |
| 09/26/2001 | EP1135515A2 Use of trans-activation and cis-activation to modulate the persistence of expression of a transgene |
| 09/26/2001 | EP1135513A1 Adenovirus-mediated gene therapy |
| 09/26/2001 | EP1135495A2 Secreted amd transmembrane polypeptides and nucleic acids encoding the same |
| 09/26/2001 | EP1135482A1 Cancer cell vaccine |
| 09/26/2001 | EP1135469A1 An improved method for the production and purification of adenoviral vectors |
| 09/26/2001 | EP1135468A1 Virus vectors and methods of making and administering the same |
| 09/26/2001 | EP1135467A1 Psca: prostate stem cell antigen and uses thereof |
| 09/26/2001 | EP1135466A2 Mammalian non-neuronal cells that are modified to store and release a neurotransmitter |
| 09/26/2001 | EP1135465A2 Human brain endothelial cells and growth medium and method for expansion of primitive cd34+cd38- bone marrow stem cells |
| 09/26/2001 | EP1135463A2 Lymphoid tissue-specific cell production from hematopoietic progenitor cells in three-dimensional devices |
| 09/26/2001 | EP1135413A2 Proteins that bind angiogenesis-inhibiting proteins, compoisitions and methods of use thereof |
| 09/26/2001 | EP1135177A1 Porous composite matrix and the production and use thereof |
| 09/26/2001 | EP1135167A2 Methods and formulations for reducing circulating antibodies |
| 09/26/2001 | EP1135164A1 Method for the treatment of inflammation |
| 09/26/2001 | EP1135161A1 Chemotherapeutic composition and method |
| 09/26/2001 | EP1135156A2 Medicinal product and method for treatment of conditions affecting neural stem cells or progenitor cells |
| 09/26/2001 | EP1135155A1 Methods of inhibiting ectopic calcification |
| 09/26/2001 | EP1135145A2 Isolated material having an anti-organotrophic effect |
| 09/26/2001 | EP0822839B1 Artificial skin containing as support biocompatible materials based on hyaluronic acid derivatives |
| 09/26/2001 | EP0767796B1 Chemotactic protein |
| 09/26/2001 | CN2449709Y Industrial apparatus for extracting biologic active enzymes from venin |
| 09/26/2001 | CN1314948A Targeted adenovirus vectors for delivery of heterologous genes |
| 09/26/2001 | CN1314939A Inhibition of graft versus host disease |
| 09/26/2001 | CN1314816A Low molecular weight compositions of shark cartilage, processes for their preparation and therapeutic uses thereof |
| 09/26/2001 | CN1314466A Urogastor coccus pure culture through separation sieving and its use |
| 09/26/2001 | CN1314177A Medicine for treating high blood pressure and preventing cerebral hemorrhage and its preparing method |
| 09/26/2001 | CN1314172A External use paste for curing burn, scald and electric shock wound |
| 09/26/2001 | CN1314170A Medicine for treating diabetes and its preparation process |
| 09/26/2001 | CN1314169A Medicine for treating hepatitis B |
| 09/26/2001 | CN1314168A Paste for eradicating liver disease and preparing method |
| 09/26/2001 | CN1314166A Mampalon penis product |
| 09/26/2001 | CN1314164A Method for preparing liver recovery decoction for curing liver disease |
| 09/26/2001 | CN1314160A Oral pill for curing diabetes and its complication |
| 09/26/2001 | CN1314159A Medicine for curing protrution of intervetebral disc and its preparing method |
| 09/26/2001 | CN1314157A Traditional Chinese medicine for curing diabetes and kidney deficiency |
| 09/26/2001 | CN1314155A Mampalon perfume and its producing method |
| 09/26/2001 | CN1071577C Medicine for curing cancer and preparing method |
| 09/25/2001 | US6294383 Porcine neural cells and their use in treatment of neurological deficits due to neurodegenerative diseases |
| 09/25/2001 | US6294377 Adenoviral vectors of canine origin |
| 09/25/2001 | US6294346 Preparing cell culture of neurospheres comprising cluster of neural stem cells, contacting with agent, and determining effect on proliferation, differentiation or survival; treatment of nervous system disorders |
| 09/25/2001 | US6294177 Particularly useful in the treatment of mastitis. |
| 09/25/2001 | US6294175 Compounds |
| 09/25/2001 | US6294172 Monoclonal antibodies with specificity for membrane-associated antigens |
| 09/25/2001 | US6294166 Nutrition supplement containing Lactobacillus acidophilus, yeast and soy protein |
| 09/25/2001 | US6294165 Vectors and their use in gene transfer. based on retroviruses, adapted so that they cannot package their own rna, and which can be used as infectious agents to transfer foreign genes, e.g. for somatic gene therapy. |
| 09/25/2001 | CA2212563C Process for obtaining medically active fractions from sea cucumbers |
| 09/20/2001 | WO2001068888A2 Production of chimeric capsid vectors |
| 09/20/2001 | WO2001068837A2 Antisense oligonucleotides of the human chk1 gene and uses thereof |
| 09/20/2001 | WO2001068828A2 Compositions and methods for regulated protein expression in gut |
| 09/20/2001 | WO2001068820A1 Altered strain of the modified vaccinia virus ankara (mva) |
| 09/20/2001 | WO2001068815A1 Embryonic stem cells and neural progenitor cells derived therefrom |
| 09/20/2001 | WO2001068814A2 Multipotent cell and cardiomyocyte cell populations, and routes to and uses of same |
| 09/20/2001 | WO2001068813A1 L-leucyl-l-leucine methyl ester treatment of donor lypmhocyte infusions in hematopoietic stem cell transplant patients |
| 09/20/2001 | WO2001068811A2 Method for in vitro production of three-dimensional vital cartilage or bone tissue and use thereof as transplant material |
| 09/20/2001 | WO2001068677A2 Derivatives of breast canacer antigen her-2 for therapeutical use |
| 09/20/2001 | WO2001068226A2 A method of sorting cells |
| 09/20/2001 | WO2001068148A1 Systemic gene delivery vehicles for the treatment of tumors |
| 09/20/2001 | WO2001068135A2 Compositions and methods for affecting osteogenesis |
| 09/20/2001 | WO2001068122A2 A method for reversing the immunosuppressive effects of the melanoma inhibitory activity 'mia' |
| 09/20/2001 | WO2001068108A1 Induction of beta cell differentiation in human cells by stimulation of the glp-1 receptor |
| 09/20/2001 | WO2001068107A1 Hair restoration formulation |
| 09/20/2001 | WO2001068085A1 A method for stimulation of defensin production |
| 09/20/2001 | WO2001067888A1 Improvements in and relating to honey based products |
| 09/20/2001 | WO2001030366A3 Use of parvoviruses for improving the general condition of tumour patients or patients having chronic or consumptive diseases |
| 09/20/2001 | WO2001019851A3 Opaminergic neuronal survival-promoting factors and uses thereof |
| 09/20/2001 | WO2001014593A3 A method for producing quality assured biological sample and composition containing the same |
| 09/20/2001 | WO2001014581A3 Hdac4 and hdac5 in the regulation of cardiac gene expression |
| 09/20/2001 | WO2001011007A3 Bioartificial device for propagation of tissue, preparation and uses thereof |
| 09/20/2001 | WO2001007065B1 PRODUCTION OF rhPBGD AND NEW THERAPEUTIC METHODS FOR TREATING PATIENTS WITH ACUTE INTERMITTENT PORPHYRIA (AIP) AND OTHER PORPHYRIC DISEASES |
| 09/20/2001 | WO2001002540A9 Adenoviral vectors for treating disease |
| 09/20/2001 | WO2000046246A8 Alpha-2-macroglobulin therapies and drug screening methods for alzheimer's disease |